Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Дашян, Г. А.; Семиглазов, В. Ф.; Krivorotko, Petr; Семиглазова, Т. Ю.; Топузов, Э Э; Палтуев, Р. М.; Зернов, Константин; Аполлонова, В. С.; Ерещенко, С. С.; Petrova, A; Жильцова, Е. К.; Иванова, О. А.

doi:10.17650/1994-4098-2016-12-1-46-51

Tumors of female reproductive system

2016

DOI: 10.17650/1994-4098-2016-12-1-46-51

|View full text |Cite

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Г. А. Дашян¹,

В. Ф. Семиглазов²,

Petr Krivorotko³

et al.

Abstract: 46М а м м о л о г и я / M a m m o l o g y 1 ' 2 0 1 6 Том 12 / Vol. 12 ОПУХОЛИ ЖЕНСКОЙ РЕПРОДУКТИВНОЙ СИСТЕМЫ TUMORS OF FEMALE REPRODUCTIVE SYSTEM Лечение После рака легких 2-й наиболее частой причиной метастазов в головной мозг (ГМ) является рак мо-лочной железы (РМЖ), метастазирование при кото-ром наблюдается в 10-16 % случаев [1]. Еще у 10 % больных происходит бессимптомное метастазирова-ние, что подтверждается данными аутопсии [2]. В по-следние годы отмечается более частое выявление метастазов в ГМ, что, в… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

High-dose stereotactic radiosurgery for large brainstem metastasis and its recurrence treatment

Romanova¹,

Zubatkina²,

Ivanov

2023

Nejrohirurgiâ (Mosk.)

View full text Add to dashboard Cite

Background. Breast cancer contributed to 11.8 % of all the oncological diseases detected in Russia in 2020 and to 21.7 % of tumors detected among women. The frequency of brain metastases is estimated at 13–32 %. It is known that HER2 positive and triple negative breast cancers metastasize to the brain more frequently.Aim. To present the case of stereotactic high‑dose irradiation for a large brainstem metastasis from HER2 positive breast cancer and re‑irradiation of the recurrence.Materials and methods. Analysis of the results of stereotactic irradiation for a large brainstem metastasis from HER2 positive breast cancer and re‑irradiation of the recurrence with a local control over five years was performed.Results. The local control after five years did not show any signs of tumor progression or post‑radiation necrosis. The patient’s Karnofsky Performance Status was estimated at 100 points.Conclusions. The case shows the necessity of highly conformal stereotactic dose delivery to the tumor, precise determination of tumor boundaries on high resolution thin slice magnetic resonance imaging, verification of recurrence using metabolic studies and hypofractionated dose delivery. It remains open whether and to what extent target therapy may contribute to local control.

show abstract

High-dose stereotactic radiosurgery for large brainstem metastasis and its recurrence treatment

Romanova¹,

Zubatkina²,

Ivanov

2023

Nejrohirurgiâ (Mosk.)

View full text Add to dashboard Cite

show abstract

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases

Vladimirova¹,

Popova²,

Abramova³

et al. 2020

Medicinskij sovet

View full text Add to dashboard Cite

Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients who are difficult to treat and have a short life expectancy. The possibilities of whole brain radiotherapy, stereotactic radiosurgery and surgery in such patients are rather limited. Trastuzumab emtansine (T-DM1) showed potential activity in this subset of patients. T-DM1 is an antibody-chemical conjugate (ADC) that delivers directly to HER2-positive cancer cells, thereby limiting damage to healthy tissue. At this point, the efficacy of trastuzumab emtansine has been demonstrated in several randomized trials as a second and subsequent lines of therapy for advanced breast cancer with a favorable toxicity profile of the drug. This article describes a clinical case of a patient with luminal B HER-2 positive breast cancer who, underwent stereotactic radiosurgery and was treated with trastuzumab emtansine as a the second line of treatment for disease progression with metastatic brain lesions after trastuzumab/pertuzumab-containing therapy. Partial regression of metastases with long-term duration of the effect was achieved treatment with trastuzumab emtazine has been being continued for 24 months. Tolerability of therapy was good: thrombocytopenia 2 degree was the main among side effects. The effect has been persisted for 2 years and the patient continues the treatment. Discussion of the results of real clinical practice with well-known studies was carried out.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Cited by 2 publications

References 44 publications

High-dose stereotactic radiosurgery for large brainstem metastasis and its recurrence treatment

High-dose stereotactic radiosurgery for large brainstem metastasis and its recurrence treatment

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases

Contact Info

Product

Resources

About